Strengthening Sales Capabilities by Moving the LAL Business to Direct Sales in Europe
First written in FY2019-Q2. 4 of 9 entries say "Advanced", first in FY2019. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3RestatedAnnual report
「Revenue was ¥7,657 million, down 6.7% year on year. Although domestic sales were broadly in line with the same period of the previous year, revenue at overseas subsidiary Associates of Cape Cod, Inc. declined as the COVID-19-related windfall subsided.」
In the overseas expansion of the LAL business, the decline in overseas sales resulting from the subsiding infectious disease-related demand surge has continued. - FY2024-Q1Overseas sales declined as the infectious disease-related demand surge subsidedAnnual report
「Domestic sales were broadly in line with the same period of the previous year, while revenue at overseas subsidiary Associates of Cape Cod, Inc. fell to ¥2,488 million, down 11.7% year on year, as the COVID-19-related windfall subsided despite a positive foreign-exchange effect.」
At the LAL business's overseas subsidiaries, net sales declined 11.7% year on year as the infectious disease-related demand surge subsided, despite the positive effect of the weaker yen. - FY2023-Q2RestatedAnnual report
「Revenue was ¥5,566 million, up 26.7% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased with stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., contract testing service orders rose, and domestic sales remained solid.」
In the LAL business, stronger sales activities by overseas subsidiaries and increased orders for contract testing services continued, resulting in a 26.7% year-on-year increase in net sales for the six months ended. - FY2023-Q1AdvancedAnnual report
「Revenue was ¥2,819 million, up 35.7% year on year, supported by solid domestic sales, higher sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products resulting from stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., and higher contract testing service orders.」
In addition to stronger sales activities in the LAL business, increased orders for contract testing services contributed to a 35.7% year-on-year increase in quarterly net sales. - FY2022-Q2AdvancedAnnual report
「Revenue was ¥4,394 million, up 33.2% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased with stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., contract testing service orders rose, and domestic sales remained solid.」
In addition to stronger sales activities in the LAL business, increased orders for contract testing services contributed to a 33.2% year-on-year increase in cumulative net sales. - FY2021-Q1AdvancedAnnual report
「Sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased on stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., bringing revenue to ¥1,844 million, up 7.7% year on year.」
The continued strengthening of sales activities by the LAL business's overseas subsidiaries produced results in the form of growth in sales of related products and a 7.7% year-on-year increase in net sales. - FY2020-Q1RestatedAnnual report
「Revenue was ¥1,712 million, up 2.8% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products performed well, supported by stronger direct sales and distributor activities at overseas subsidiary Associates of Cape Cod, Inc.」
In the LAL business, efforts to strengthen both direct sales and distributor-based sales in Europe and elsewhere continued, and related products performed steadily. - FY2019AdvancedAnnual report
「At overseas subsidiary Associates of Cape Cod, Inc., sales of in vitro diagnostic reagents for glucan measurement, in addition to reagents for endotoxin measurement, are growing as sales activities through both direct channels and distributors are strengthened.」
In the LAL business, sales activities through both direct channels and distributors in Europe and elsewhere were strengthened, and sales of in vitro diagnostic reagents for glucan measurement also grew in addition to endotoxin reagents. - FY2019-Q2First statedAnnual report
「At overseas subsidiary Associates of Cape Cod, Inc., efforts to strengthen sales capabilities in Europe include transitioning from sales through distributors to direct sales. Sales of in vitro diagnostic reagents for glucan measurement, in addition to reagents for endotoxin measurement, are growing.」
The company first disclosed measures to strengthen sales capabilities by transitioning the LAL business in Europe from distributor-based sales to direct sales. It also mentioned growth in sales of in vitro diagnostic reagents for glucan measurement.